Walter Reed Cleared the Implant. Now the Hospital Is the Manufacturer.

Someone at Walter Reed decided the hospital would hold the clearance itself. Not the vendor, not a contract manufacturer. On July 28, 3D Systems announced that the 3D Medical Applications Center at Walter Reed National Military Medical Center had won FDA clearance for the 3D MAC Titanium Cranial Plate System under K253116, the first cleared implant ever held by a point-of-care institution. The plate is a good piece of engineering. The bigger news is that a hospital is now the manufacturer of record on an implant.

The device is a patient-specific titanium plate that reconstructs cranial and facial defects after trauma, disease, or cancer, and it will be used on active duty personnel with traumatic head injuries. Dr. Peter Liacouras, who directs services at 3D MAC, designed it. They cleared it on their first 510(k) submission.

What the clearance holder actually signs up for

Holding a 510(k) means being the manufacturer of record, and that title carries a long list of standing obligations. Design controls. Complaint handling. Corrective and preventive action. Adverse event reporting. Supplier controls. Process and sterilization validation. A quality system that has to survive an FDA inspection, operated by an institution whose actual job is treating patients. Then layer on the fact that these implants are patient-specific, so the design record is not written once and filed away. It regenerates with every skull.

3D Systems did real work here. The company supplied process control expertise, design optimization, additive manufacturing workflow guidance, regulatory strategy, and help standing up the quality system, and its CEO Jeff Graves framed point-of-care manufacturing as bringing personalized devices closer to the patient. But 3D Systems did not take the clearance. Walter Reed did. That matters, because the entity named on the clearance is the one that has to live inside the quality system for as long as the device exists.

I once paid about $480,000 for blue ink

At Galen, our bill with Hogan Lovells on the De Novo came to something like $480,000. My board insisted on the brand-name firm, end to end. Meanwhile our own internal people were writing the documentation. The regulatory work product was being produced inside the company, by the engineers and clinicians who understood the device. What the board was really buying was the signature on it, because a recognizable firm changes how the next investor reads the file.

That has value and I want to be fair about it. The submission cleared eleven days after we filed, so the firm probably did buy us some certainty. But I was paying premium hourly rates for regulatory thinking that belonged with a specialist consultant at a fraction of the price, on top of the engineering and clinical work that produced the document in the first place. I got disciplined about it eventually, logging every billable call and reading the invoices line by line. I told them I was not paying for ten minutes of pleasantries at the top of every call.

The pattern I have run ever since, across IP portfolios, stock option plans, cadaver studies, and FDA work, is to learn enough to do about ninety percent of it myself, pay the expensive experts to tell me what to go figure out, then hand it back for the final refinement. That is roughly the shape of what Walter Reed did. They kept the design, the manufacturing, and the ownership. They bought the expertise they did not have.

What the clearance actually covers

Walter Reed intends to distribute the system to other point-of-care facilities across the Department of Defense, and possibly into the VA. The plan includes design hubs, where other military institutions submit device files and Walter Reed manufactures them. Scans, design, and production all happen in house.

That turns the clearance into a distribution plan. A clearance written around a process rather than one finished good lets an institution extend the capability to its peers, and it puts Walter Reed in the position every other DoD facility now has to route through. The version of this that applies to a founder is simpler. If your product only works when it is built or fitted close to the patient, you have already decided that somebody out near the patient runs a quality system. That is not a manufacturing detail you get to settle after the design freeze. It sets who your customer is, what you can charge, and who carries the regulatory burden when something goes wrong.

Dave Saunders is the founder of Base Reality Group and a Fractional CPO for hard-tech founders. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →